Fox Chase Cancer Center’s Dr. Mary Daly Receives Inaugural Impact Award From Basser Center for BRCA

Dr. Daly Group
Mary Daly, MD, PhD, FACP, was recently recognized as the first recipient of the BRCA Impact Award from Penn Medicine’s Basser Center for BRCA.  

PHILADELPHIA (May 22, 2023)—Fox Chase Cancer Center’s Mary Daly, MD, PhD, FACP, a professor in the Department of Clinical Genetics and the Timothy R. Talbot Jr. Chair in Cancer Research, was recently recognized as the first recipient of the BRCA Impact Award from Penn Medicine’s Basser Center for BRCA.

The award was created to recognize a national leader in the field of cancer genetics. The Basser Center for BRCA at Penn Medicine’s Abramson Cancer Center has helped to accelerate BRCA-related cancer research and the development of targeted therapies. BRCA1 and BRCA2 are tumor suppressor genes that can lead to the development of cancer when mutated.

“Receiving this award made me think back to what I’ve done here at Fox Chase, because when you go to work every day you don’t think you’re making an impact, you just think you’re doing your job and taking care of patients,” said Daly.

“It made me realize, looking back over all the years that I’ve been here, that I have made an impact in terms of setting up one of the first risk-assessment programs for cancer prevention even before we knew about the cancer genes,” she added.

“The Basser Center for BRCA is committed to advancing BRCA1/2-related research by working with collaborators across the world to make progress for patients and families affected by BRCA mutations,” said Susan M. Domchek, MD, the center’s director. “With the inaugural BRCA Impact Award, we’re excited to honor a cancer genetics leader here in Philadelphia, the distinguished Mary Daly, whose work has impacted so many in our region and beyond.”

Daly is a leader in the design of educational programs in cancer genetics and cancer risk for both high-risk individuals and their healthcare providers and is a prominent researcher in the field of clinical cancer genetics.

She was the founder of the Risk Assessment Program at Fox Chase, formerly the Margaret Dyson Family Risk Assessment Program. Founded in 1991, it was the first program of its kind in the region and one of the first in the U.S. The program, which initially focused on assessing ovarian and breast cancer risk, now also includes risk assessment for several types of cancer, including prostate, gastrointestinal, lung, melanoma, and kidney.

The goal of the program is to help those at high risk of developing cancer learn about risk factors and preventive measures. It provides education, individualized counseling, genetic testing, and screening to high-risk patients.

In addition, Daly chairs the Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Panel for the National Comprehensive Cancer Network and is a member of the National Cancer Institute-sponsored PDQ Cancer Genetics Board.

“Not only have we had a good counseling program that serves people in terms of determining what their cancer risks are and how they can manage and reduce that risk, but also all of the research that has come out of it by sharing our database with other people,” said Daly. “So it has, I think, had quite an impact, because we share our data with investigators all over the world.”

Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence six consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

For more information, call 888-369-2427